Date: 2015-09-02
Type of information: Development agreement
Compound: FluMist® Quadrivalent
Company: AstraZeneca (UK) Daiichi Sankyo (Japan)
Therapeutic area: Infectious diseases
Type agreement: development commercialisation
Action mechanism: vaccine. FluMist® Quadrivalent is formulated to contain four live attenuated influenza virus strains that are weakened so as to not cause illness. The vaccine is administered by spraying into each nostril where it induces protective immunity.This flu vaccines contains four strains of influenza: two influenza A viruses (H1N1 and H3N2) and two influenza B virus. The most common adverse reactions for Fluenz Tetra® include runny nose or nasal congestion.
Disease: influenza
Details: * On September 2, 2015, Daiichi Sankyo announced that Daiichi Sankyo and the global biologics research and development arm of AstraZeneca, MedImmune LLC, has entered into an agreement regarding an exclusive license to develop and commercialize FluMist® Quadrivalent in Japan. Phase III safety and efficacy studies were conducted for FluMist Quadrivalent in Japanese children over the 2014-2015 influenza season and a regulatory submission is being prepared in Japan. Daiichi Sankyo will take on the full responsibility for the future development and commercialization of FluMist Quadrivalent in Japan and will hold the marketing authorisation; AstraZeneca will supply FluMist Quadrivalent to Daiichi Sankyo. The agreement builds on the successful collaborations between AstraZeneca and Daiichi Sankyo, such as the co-commercialization of Nexium® in Japan and Movantik™ (naloxegol) in the US.
Financial terms: Under the terms of the agreement, Daiichi Sankyo will pay AstraZeneca an upfront fee with subsequent development milestones and sales-related payments post launch.
Latest news:
